Key result
Aggressive antithrombotics and early PCI yield greater benefit in diabetic versus non-diabetic UA/NSTEMI patients.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May support risk-stratified aggressive therapy in diabetic UA/NSTEMI-ACS; hypothesis-generating and requires RCT confirmation.
Treatment of ACS in Diabetic Patients in Western Region of Saudi Arabia In the setting of UA/NSTEMI-ACS, diabetes mellitus was found to be an independent predictor of mortality and DM patients were found to derive greater benefit than non-DM counterparts from aggressive antithrombotic therapy, early coronary angiography, and stent-based percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Abdulhalim Jamal Kinsara (2013) studied this question. Aggressive antithrombotic therapy, early coronary angiography, and stent-based PCI provide greater benefit to diabetic patients with UA/NSTEMI-ACS compared to non-diabetic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: